
|Articles|March 8, 2010
- October 2009
- Volume 0
The Challenge of Proving Cetuximab's Value in Metastatic Colorectal Cancer
Author(s)Onclive Team
Key Takeaways
Advertisement
Articles in this issue
almost 16 years ago
Attitude Counts at U-M Comprehensive Cancer Centeralmost 16 years ago
Baby Biotechs Walk 'Valley of Death; in Search of Fundingalmost 16 years ago
A Global Look at H1N1almost 16 years ago
2009 Breast Cancer Symposiumalmost 16 years ago
Tyrosine Kinase Inhibitors in CMLAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
5



































